Patient

ARE YOU A COMMUNITY MEDICAL OR RADIATION ONCOLOGIST?

  • Interested In Starting A Radiopharmaceutical Program At Your Center But Seems Complex?
  • Interested In Conducting Radiopharmaceutical Clinical Trials But Have No Current Or Limited Clinical Trials Program
  • Interested In Helping Fill The Critical Shortage Of Community Cancer Centers Capable Of Conducting Radiopharmaceutical Clinical Trials

XCancer® has the experts and the experience to provide your center with the backbone, tools, strategies, and business models to make you successful at both. XCancer® is a community cancer center with a solo medical oncologist that has developed a leading radiopharmaceutical clinical trials program recognized globally. Using its experience and processes, XCancer® has successfully guided community cancer centers across the United States with developing highly efficient and quality clinical trial programs.

Start your program today:

info@theranostictrials.org or drluke@xcancer.com

Physicians

Advanced Knowledge & Opportunites

  • Advance your Knowledge of Theranostics, Radiation, & Clinical Trials
  • Search a Comprehensive List of Global Oncology-Theranostic clinical trials
  • Easy access to Publications & Presentations regarding investigational Theranostic agents
  • Opportunities & Access to Strategy Advisors on How to Develop a Theranostic Clinical Trials Program at Your Site
  • Access to Clinical Trials Sponsors in search of potential clinical trial sites
  • Keep updated of Upcoming Theranostic Conferences
DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Luke T. Nordquist, MD

Dr. Luke Nordquist is a Medical Oncologist with an expertise in Prostate Cancer. He is the Founder and CEO of XCancer® in Omaha, NE. Dr. Luke and the XCancer® team are globally recognized for their many contributions to the advancement of novel imaging and therapies for prostate cancer. The XCancer® team are often considered as a go to site for rapid startup, phase 1 trials because of their focus, quality and exceptional efficiency. XCancer® has the ability to open a clinical trial in a few weeks. As of 2024, Dr. Luke and his team have accrued more than 1500 patient to clinical trials and conducted more than 20 First-in-World clinical trials for Prostate Cancer. They have extensive experience with many radioisotopes having conducted more than 40 radiopharmaceutical imaging and therapeutic trials. His team accrued the first patient, the most patients and had the highest quality data on the Lu177 PSMA Vision Trial. More than 450 prostate cancer patients every month from more than 40 states and several countries travel to Dr. Luke in Omaha for their prostate cancer care. To improve education, awareness, and access to radiopharmaceutical clinical trials globally, Dr. Luke developed TheranosticTrials.org. XCancer® also has developed a strategic program, business knowledge, and training curriculum to assist other Medical Oncologists & Community Cancer Centers from coast to coast in developing radiopharmaceutical programs that are able to conduct early to late phase clinical trials. XCancer® is helping assist cancer care as far away as Tanzania, Africa. The XCancer® Foundation, funded the construction of a cancer housing hostel at the Kilimanjaro Christian Medical Center (KCMC) in Moshi, Tanzania. Omaha, NE USA Contact Information: For Patient Appointments: Patient Advocate Desk: 402-991-8468 For Clinical Trials: Tony Romero 402-991-8468 For Industry/Business Meetings: Stacy Moore 402-991-8468 drluke@xcancer.com

Read More >>

See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTS Tab.

View RLT Components

Education


banana

Stats

Theranostic Trials Global Ecosystem

View All

Loading...
Loading...

Conferences


Loading...

Sponsors

Loading...